Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer ImmunotherapyBusiness Wire (press release)Immunotherapy has become prominent in recent years as a result of remarkable response rates seen in previously unresponsive ca… Continue reading
KC RegisterAllergan to pay Editas $90m for development of CRISPR eye treatmentLife Sciences Intellectual Property Review (subscription)Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and develo… Continue reading
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell ServicesYahoo FinanceCAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today an… Continue reading
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell ServicesGlobeNewswire (press release)CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging … Continue reading
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell ServicesGlobeNewswire (press release)CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging … Continue reading
|
Cesca Therapeutics (KOOL) Announces CLI Feasibility Study Published in Stem Cells International
StreetInsider.com The report was published in the “Stem Cells International” and is available online at https://www.hindawi.com/journals/sci/2017/4137626/ref/. Results from the seventeen patient clinical study titled, “Safety and Effectiveness of Bone Marrow Cell … |